Page last updated: 2024-10-28

haloperidol and Neoplasms

haloperidol has been researched along with Neoplasms in 61 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Treatment of delirium often includes haloperidol."9.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)."9.30Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019)
"Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016."9.24Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017)
"Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use."9.14The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010)
"Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage."9.08Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996)
"This was a preplanned secondary analysis of a double-blind randomized clinical trial examining the sedative effect of chlorpromazine and/or haloperidol in patients with agitated delirium."5.41Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication. ( Bruera, E; De La Rosa, A; Hui, D; Nguyen, T; Urbauer, DL, 2021)
"Treatment of delirium often includes haloperidol."5.34Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020)
"The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)."5.30Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019)
"The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium."5.27The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018)
"Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016."5.24Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017)
"The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting."5.19A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014)
"Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use."5.14The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010)
"Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage."5.08Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996)
"Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens."5.05Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. ( Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984)
" Inquiries were made regarding: (i) choice of drug class in the first-line treatment, (ii) administration methods of the first-line antipsychotic treatment, (iii) starting dose of antipsychotics in the first line treatment and maximum dose of antipsychotics in refractory delirium, and (iv) choice of treatment when the first-line haloperidol treatment failed."4.12Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists. ( Kashiwagi, H; Matsuda, Y; Morita, T; Naito, AS; Otani, H; Oya, K; Tagami, K, 2022)
"To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)."3.83Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016)
"More than 2,000 medically ill patients with delirium have been treated by intravenous administration of a combination of haloperidol and lorazepam."3.67Emergency intravenous sedation of the delirious, medically ill patient. ( Adams, F, 1988)
"A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely."3.67Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988)
"Eleven patients with various cancer types from ten case reports published from 1988 to 2013 met the eligibility criteria."2.66Neuroleptic malignant syndrome in patients with cancer: a systematic review. ( Ishida, M; Kawakami, K; Kawanishi, C; Onishi, H; Sato, I; Yamada, S, 2020)
"Delirium is the most common and distressing neuropsychiatric syndrome in cancer patients."2.53Neuroleptics in the management of delirium in patients with advanced cancer. ( Bruera, E; Dev, R; Hui, D, 2016)
"Delirium is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of people with terminal illness in the last days of life."2.45Delirium at the end of life. ( Keeley, PW, 2009)
"Delirium is the second most common psychiatric diagnosis among hospitalized elderly cancer patients."2.38Delirium in cancer patients. ( Holland, J; Stiefel, F, 1991)
" Limited information is available regarding the dosage requirements and efficacy of neuroleptics in the palliative care setting."1.36Neuroleptic dose in the management of delirium in patients with advanced cancer. ( Bruera, E; Bush, SH; Gallo, LE; Hui, D; Palmer, JL; Yennurajalingam, S, 2010)
"Haloperidol has been found to be very efficient in controlling agitation with or without pain, nausea and/or vomiting of central origin, intestinal obstruction, and delirium."1.33Stability of tramadol and haloperidol for continuous subcutaneous infusion at home. ( Azuara, ML; Barcia, E; Martín, A; Negro, S; Sánchez, Y, 2005)
"Haloperidol was precipitated at a concentration of >/=1."1.32Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. ( Barcia, E; Luz Azuara, M; Negro, S; Reyes, R; Sánchez, Y, 2003)
"At the time of peak hyperalgesia, WIN55,212-2 (1-30mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0."1.32A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. ( Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL, 2003)
" The mean dosage for midazolam was 18."1.32Use of sedation to relieve refractory symptoms in dying patients. ( Blitz-Lindeque, J; Bridge, D; Cameron, D, 2004)
"Depression in cancer patients is common and occurs throughout the course of cancer illness."1.31[Management of psychiatric symptoms in cancer patients]. ( Uchitomi, Y, 2002)
"Delirium in the cancer patient is particularly problematic given the coexisting medical problems these patients experience."1.29A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. ( Baile, WF; Meyers, CA; Olofsson, SM; Valentine, AD; Weitzner, MA, 1996)
"20 patients with neuropathic pain syndromes due to tumor-infiltration, who had not responded to conventional analgesics including strong opioids, received additional combination anti-convulsant and anti-depressant treatment."1.28Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients. ( Höffken, K; Kloke, M; Olbrich, H; Schmidt, CG, 1991)
" A dosing strategy for the combbination of clomipramine and haloperidol is described."1.26[The treatment of chronic pain symptoms with psychotropic drugs (author's transl)]. ( Kocher, R, 1976)

Research

Studies (61)

TimeframeStudies, this research(%)All Research%
pre-199016 (26.23)18.7374
1990's7 (11.48)18.2507
2000's12 (19.67)29.6817
2010's20 (32.79)24.3611
2020's6 (9.84)2.80

Authors

AuthorsStudies
John, CS1
Lim, BB1
Vilner, BJ1
Geyer, BC1
Bowen, WD1
Diamandis, P1
Wildenhain, J1
Clarke, ID1
Sacher, AG1
Graham, J1
Bellows, DS1
Ling, EK1
Ward, RJ1
Jamieson, LG1
Tyers, M1
Dirks, PB1
Mach, RH1
Zeng, C1
Hawkins, WG1
Weber, F1
Brune, S1
Korpis, K1
Bednarski, PJ1
Laurini, E1
Dal Col, V1
Pricl, S1
Schepmann, D1
Wünsch, B1
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Lindsley, CW1
Hopkins, CR1
Amata, E1
Dichiara, M1
Arena, E1
Pittalà, V1
Pistarà, V1
Cardile, V1
Graziano, ACE1
Fraix, A1
Marrazzo, A1
Sortino, S1
Prezzavento, O1
Matsuda, Y2
Morita, T1
Oya, K1
Tagami, K1
Naito, AS1
Kashiwagi, H1
Otani, H1
van der Vorst, MJDL1
Neefjes, ECW1
Boddaert, MSA1
Verdegaal, BATT1
Beeker, A1
Teunissen, SCC1
Beekman, ATF1
Wilschut, JA1
Berkhof, J1
Zuurmond, WWA1
Verheul, HMW1
Sato, I1
Onishi, H1
Kawanishi, C1
Yamada, S1
Ishida, M1
Kawakami, K1
Hui, D7
De La Rosa, A2
Wilson, A2
Nguyen, T3
Wu, J1
Delgado-Guay, M2
Azhar, A1
Arthur, J2
Epner, D2
Haider, A1
De La Cruz, M2
Heung, Y1
Tanco, K2
Dalal, S2
Reddy, A3
Williams, J2
Amin, S2
Armstrong, TS1
Breitbart, W2
Bruera, E7
Zhu, J1
Xiong, Y1
Zhang, Y1
Wen, J1
Cai, N1
Cheng, K1
Liang, H1
Zhang, W1
Urbauer, DL1
Frisbee-Hume, S1
Dibaj, SS2
Walker, P1
Zhukovsky, DS1
Vidal, M1
Hall, S1
Liu, D1
Hess, K2
Dev, R2
Reddy, S1
Shrikant Kulkarni, N1
Dulal, S1
Paudel, BD1
Neupane, P1
Shah, A1
Acharya, B1
Poudyal, BS1
Shilpakar, R1
Wood, LA1
Fletcher, DS1
Coyne, PJ1
Dodson, PW1
Parker, GG1
Wan, W1
Smith, TJ1
Tanimukai, H1
Tsujimoto, H1
Tokoro, A1
Kanemura, S1
Watanabe, M1
Tsujio, I1
Maeda, I1
Takei, K1
Nakajima, S1
Taira, T1
Tokuyama, M1
Kai, T1
Okamoto, Y1
Goya, S1
Kashiwagi, Y1
Boušová, I1
Skálová, L1
Souček, P1
Matoušková, P1
Bush, SH1
Gallo, LE1
Palmer, JL1
Yennurajalingam, S1
Hardy, JR1
O'Shea, A1
White, C1
Gilshenan, K1
Welch, L1
Douglas, C1
Keeley, PW1
Palla, S1
Radha Krishna, LK1
Poulose, VJ1
Goh, C1
Kim, FJ1
Schrock, JM1
Spino, CM1
Marino, JC1
Pasternak, GW1
Uchitomi, Y2
Barcia, E3
Reyes, R2
Luz Azuara, M1
Sánchez, Y3
Negro, S3
Kehl, LJ1
Hamamoto, DT1
Wacnik, PW1
Croft, DL1
Norsted, BD1
Wilcox, GL1
Simone, DA1
Cameron, D1
Bridge, D1
Blitz-Lindeque, J1
Martín, A1
Azuara, ML2
Guo, SL1
Lin, CJ1
Huang, HH1
Chen, LK1
Sun, WZ1
Ito, H1
Harada, D1
Hayashida, K1
Ishino, H1
Nakayama, K1
Bleicher, J1
Bhaskara, A1
Huyck, T1
Constantino, S1
Bardia, A1
Loprinzi, CL1
Silberstein, PT1
Grunberg, SM1
Gala, KV1
Lampenfeld, M1
Jamin, D1
Johnson, K1
Cariffe, P1
Strych, D1
Krailo, M1
Breivik, H1
Rennemo, F1
Olofsson, SM1
Weitzner, MA1
Valentine, AD1
Baile, WF1
Meyers, CA1
Akechi, T1
Okamura, H1
Fukue, M1
Kagaya, A1
Nishida, A1
Oomori, N1
Yamawaki, S1
Mickle, J1
Critchley, P1
Plach, N1
Grantham, M1
Marshall, D1
Taniguchi, A1
Latimer, E1
Jadad, AR1
Kocher, R2
Ottesen, S1
Monrad, L1
Stiefel, F1
Holland, J1
Kloke, M1
Höffken, K1
Olbrich, H1
Schmidt, CG1
Adams, F3
Murakami, M1
Ota, K1
Fernandez, F2
Holmes, VF1
Kavanaugh, JJ1
Andersson, BS1
Maisami, M1
Sohmer, BH1
Coyle, JT1
Saller, R1
Hellenbrecht, D1
Plotkin, DA1
Plotkin, D1
Okun, R1
Sirtori, C1
Cole, DR1
Duffy, DF1
Rohrer, G1
Aydın, M1
Tóth, Z1
Czoma, V1
Bittersohl, G1
Bittersohl, J1
Iavorovskiĭ, AP1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733]101 participants (Actual)Interventional2010-03-31Completed
Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit[NCT03021486]Phase 2/Phase 370 participants (Actual)Interventional2017-06-05Active, not recruiting
A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit[NCT01949662]Phase 293 participants (Actual)Interventional2014-01-31Active, not recruiting
HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023]Phase 372 participants (Anticipated)Interventional2022-05-18Recruiting
Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395]Phase 280 participants (Anticipated)Interventional2021-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in RASS Score (0-30 Minutes)

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 30 minutes later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 30 minutes later.

Interventionscore on a scale (Mean)
Escalation Group-2.6
Rotation Group-2.4
Combination Group-2.1

Change in Richmond Agitation Sedation Score (RASS) (0-24h)

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours after study medication administration

Interventionscore on a scale (Mean)
Escalation Group-3.6
Rotation Group-3.3
Combination Group-3.0

Memorial Delirium Assessment Scale (MDAS)

The Memorial Delirium Assessment Scale (MDAS) is a 10-item clinician-rated assessment scale validated for assessment of delirium in cancer patients. It examines the level of consciousness, disorientation, memory, recall, attention, disorganized thinking, perceptual disturbance, delusions, psychomotor activity and sleep, assigning a score between 0 to 3, for a total score between 0-30. A total score of 13 or higher indicates delirium. We measured the change in Memorial Delirium Rating scale between baseline and 24 hours. (NCT03021486)
Timeframe: Baseline and 24 hours

Interventionscore on a scale (Mean)
Escalation Group-2.7
Rotation Group1
Combination Group0.3

Number of Participants With RASS Score of >=1

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was the proportion of breakthrough restlessness participants with a RASS score of >=1 during the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: 0 or Baseline and 24 hours later

InterventionParticipants (Count of Participants)
Escalation Group12
Rotation Group7
Combination Group9

Percentage of Participants With RASS Score -2 to 0

RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The Secondary outcome was the percentage of participants with target RASS score of -2 to 0 within the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours later.

InterventionParticipants (Count of Participants)
Escalation Group2
Rotation Group3
Combination Group5

Change in Delirium Experience Questionnaire

This 14-item questionnaire examines both the recalled frequency of 7 delirium symptoms and associated distress in the rater: disorientation to time, disorientation to place, visual hallucinations, tactile hallucinations, auditory hallucinations, delusional thoughts and psychomotor agitation. The score for recalled frequency ranges between 0 and 4, where 0=not present, 1=a little of the time, 2=some of the time, 3=good part of the time, and 4=most or all of the time. The score for distress in the rater related to each delirium symptom also ranges from 0 to 4, where 0=no distress, 1=a little, 2=a fair amount, 3=very much and 4=extremely distressed. Due to an error in the data collection form, the last category was omitted as a choice and thus the score only ranged from 0 to 3. (NCT03021486)
Timeframe: Baseline and Day 3

,,
Interventionscore on a scale (Mean)
Nursing assessment, disorientation to time - frequencyNursing assessment, disorientation to place - frequencyNursing assessment, visual hallucination - frequencyNursing assessment, tactile hallucination - frequencyNursing assessment, auditory hallucination - frequencyNursing assessment, delusional thoughts - frequencyNursing assessment, psychomotor agitation- frequencyNursing assessment, disorientation to time - distressNursing assessment, disorientation to place - distressNursing assessment, visual hallucination - distressNursing assessment, tactile hallucination - distressNursing assessment, auditory hallucination - distressNursing assessment, delusional thoughts - distressNursing assessment, psychomotor agitation - distress
Combination Group0.20.3-0.7-0.9-0.40.2-0.4-0.5-0.4-0.4-0.5-0.2-0.1-0.8
Escalation Group-0.8-0.9-1-0.4-0.1-0.8-1.2-0.3-0.3-0.6-0.5-0.3-0.6-0.8
Rotation Group-0.8-0.800.10.10-0.8-0.3-0.30.1000-0.5

Edmonton Expression Assessment System, ESAS

Edmonton Symptom Assessment System (ESAS) has been validated and widely used in different clinical settings, including the acute palliative care unit. It assessed the average symptom intensity of 10 symptoms over the past 24 hours. Each symptom was assessed using an 11-point numeric rating scale, ranging from 0 (none) to 10 (worst). It was measured as change in ESAS as Perceived by Caregivers between baseline and day 1, mean. (NCT03021486)
Timeframe: Baseline and 24 hours

,,
Interventionscore on a scale (Mean)
PainFatigueNauseaDepressionAnxietyDrowsinessAppetiteFeeling of well being*Shortness of breathSleep
Combination Group-1.11-0.4-0.8-0.90.70.100-2.7
Escalation Group-1.3-0.50.1-1.4-1.5-0.2-0.30.20.8-2.7
Rotation Group-4.1-3-1.8-1.2-4.8-0.6-0.6-1.6-2.2-5.1

Pattern of Medication Use

Use of neuroleptics and benzodiazepines during the first 24 hours was retrieved from the Medication Administration Record. (NCT03021486)
Timeframe: Baseline and 24 hours

,,
InterventionParticipants (Count of Participants)
Need for study med dose escalation in first 24 hrsBenzodiazepine use in first 24 hrs (scheduled)Benzodiazepine use in first 24 hrs (as needed)
Combination Group704
Escalation Group410
Rotation Group100

Perceived Comfort Level as Assessed by Caregiver

"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour

,,
InterventionParticipants (Count of Participants)
Perceived To Have A High Level of Comfort (More Comfortable)Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group66
Escalation Group89
Rotation Group1010

Perceived Comfort Level as Assessed by Nurse

"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour

,,
InterventionParticipants (Count of Participants)
Perceived To Have A High Level of Comfort (More Comfortable)Perceived To Have A Low Level of Agitation (Less Agitated)
Combination Group77
Escalation Group98
Rotation Group98

Udvalg for Kliniske Undersogelser, UKU

We also documented the selected adverse effects associated with neuroleptics using the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale. Specifically, we assessed 8 neurologic symptoms (dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). We are reporting only the neurologic symptoms (tremor and akathisia) that had changes during the study. Each item was assigned a score by the research coordinator 0 (absent) to 3 (most severe) based on symptom severity of the last 3 days. (NCT03021486)
Timeframe: Baseline and 3 days

,,
InterventionParticipants (Count of Participants)
Tremor (decreased)Akathisia (decreased)
Combination Group11
Escalation Group00
Rotation Group00

Absolute Richmond Agitation-Sedation Scale Score at 8 Hour, Points

Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: 8 hours

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-2.5
Control Group (Placebo & Haloperidol)-0.7

Change in Richmond Agitation-Sedation Scale Score (Baseline to 8 hr), Points

The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-4.1
Control Group (Placebo & Haloperidol)-2.3

Change in Richmond Agitation-Sedation Scale Score From Baseline to 30 Min

Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 30 minutes

Interventionscore on a scale (Mean)
Intervention Group (Lorazepam & Haloperidol)-3.6
Control Group (Placebo & Haloperidol)-1.6

Number of Participants With Richmond Agitation-Sedation Scale Score >=1 Within 8 hr

Number of participants with Richmond Agitation-Sedation Scale score >=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours

InterventionParticipants (Count of Participants)
Intervention Group (Lorazepam & Haloperidol)8
Control Group (Placebo & Haloperidol)22

Reviews

13 reviews available for haloperidol and Neoplasms

ArticleYear
The σ2 receptor: a novel protein for the imaging and treatment of cancer.
    Journal of medicinal chemistry, 2013, Sep-26, Volume: 56, Issue:18

    Topics: Animals; Cell Proliferation; Drug Discovery; Humans; Molecular Imaging; Molecular Probes; Neoplasms;

2013
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Return of D
    Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

    Topics: Animals; Drug Discovery; Humans; Ligands; Molecular Targeted Therapy; Neoplasms; Parkinson Disease;

2017
Neuroleptic malignant syndrome in patients with cancer: a systematic review.
    BMJ supportive & palliative care, 2020, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dantrolene; Dopamine D2 Receptor Antagonists;

2020
The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.
    Oxidative medicine and cellular longevity, 2020, Volume: 2020

    Topics: Acetaminophen; Antineoplastic Agents; Antioxidants; Apoptosis; Artemisinins; Auranofin; Cell Death;

2020
The modulation of carbonyl reductase 1 by polyphenols.
    Drug metabolism reviews, 2015, Volume: 47, Issue:4

    Topics: Alcohol Oxidoreductases; Animals; Bupropion; Butanones; Butyrophenones; Daunorubicin; Doxorubicin; G

2015
Neuroleptics in the management of delirium in patients with advanced cancer.
    Current opinion in supportive and palliative care, 2016, Volume: 10, Issue:4

    Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloper

2016
Delirium at the end of life.
    BMJ clinical evidence, 2009, Jul-16, Volume: 2009

    Topics: Analgesics, Opioid; Antipsychotic Agents; Barbiturates; Delirium; Haloperidol; Humans; Incidence; Ne

2009
Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review.
    Journal of pain and symptom management, 2001, Volume: 22, Issue:2

    Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms; Palliative Care; Vomiting

2001
Delirium in cancer patients.
    International psychogeriatrics, 1991,Winter, Volume: 3, Issue:2

    Topics: Aged; Delirium; Diagnosis, Differential; Haloperidol; Humans; Lorazepam; Neoplasms; Neuropsychologic

1991
[Recent advances in the management of chemotherapy-induced emesis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:3 Pt 1

    Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy,

1986
[The genotoxic effect of epichlorohydrin and epoxy resins].
    Archiv fur Geschwulstforschung, 1989, Volume: 59, Issue:3

    Topics: Berlin; Chlorohydrins; Epichlorohydrin; Epoxy Resins; Female; Humans; Male; Mutation; Neoplasms; Occ

1989
[Problems of work hygiene and toxicology in the present-day manufacture of plastics of an epoxy resin base (review of the literature)].
    Gigiena truda i professional'nye zabolevaniia, 1986, Issue:1

    Topics: Air Pollutants, Occupational; Animals; Chemical Industry; Dermatitis, Contact; Dermatitis, Occupatio

1986

Trials

14 trials available for haloperidol and Neoplasms

ArticleYear
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
    The oncologist, 2020, Volume: 25, Issue:3

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine;

2020
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:7

    Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; H

2020
Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.
    Cancer, 2021, Dec-15, Volume: 127, Issue:24

    Topics: Communication; Delirium; Goals; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Units;

2021
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
    JAMA, 2017, 09-19, Volume: 318, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me

2017
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.
    Cancer, 2018, 05-15, Volume: 124, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo

2018
Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients.
    American family physician, 2018, Feb-15, Volume: 97, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Female; H

2018
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
    Journal of global oncology, 2019, Volume: 5

    Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo

2019
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
    Journal of pain and symptom management, 2014, Volume: 48, Issue:5

    Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine;

2014
The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer.
    Journal of pain and symptom management, 2010, Volume: 40, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Ha

2010
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Drug Evaluati

1984
Usage of haloperidol for delirium in cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:5

    Topics: Aged; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guidelines a

1996
[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
    Klinische Wochenschrift, 1985, May-02, Volume: 63, Issue:9

    Topics: Cisplatin; Dose-Response Relationship, Drug; Haloperidol; Humans; Metoclopramide; Neoplasms; Risk; T

1985
Haloperidol for radiation sickness: Control of associated nausea, vomiting, and anorexia.
    New York state journal of medicine, 1974, Volume: 74, Issue:9

    Topics: Adult; Aged; Clinical Trials as Topic; Feeding and Eating Disorders; Female; Haloperidol; Humans; Ma

1974
[Treatment of severe chronic pains with a combination of thymoleptics and neuroleptics (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1974, Dec-31, Volume: 63, Issue:52

    Topics: Adult; Antidepressive Agents; Atropine; Chlorpromazine; Clinical Trials as Topic; Clomipramine; Drug

1974

Other Studies

34 other studies available for haloperidol and Neoplasms

ArticleYear
Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents.
    Journal of medicinal chemistry, 1998, Jul-02, Volume: 41, Issue:14

    Topics: Animals; Binding, Competitive; Brain; Guinea Pigs; Iodine Radioisotopes; Isotope Labeling; Ligands;

1998
Chemical genetics reveals a complex functional ground state of neural stem cells.
    Nature chemical biology, 2007, Volume: 3, Issue:5

    Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic

2007
Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
    Journal of medicinal chemistry, 2014, Apr-10, Volume: 57, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Chromatography, Thin Layer; Guinea Pigs; Humans; M

2014
Novel Sigma Receptor Ligand-Nitric Oxide Photodonors: Molecular Hybrids for Double-Targeted Antiproliferative Effect.
    Journal of medicinal chemistry, 2017, 12-14, Volume: 60, Issue:23

    Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Humans; Light; MCF-7 Cells; Neo

2017
Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists.
    Japanese journal of clinical oncology, 2022, 08-05, Volume: 52, Issue:8

    Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Japan; Neoplasms; Palliative C

2022
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
    The American journal of hospice & palliative care, 2016, Volume: 33, Issue:5

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F

2016
Neuroleptic dose in the management of delirium in patients with advanced cancer.
    Journal of pain and symptom management, 2010, Volume: 39, Issue:2

    Topics: Adult; Affective Symptoms; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Delirium; Dose

2010
Neuroleptic prescription pattern for delirium in patients with advanced cancer.
    Journal of palliative care, 2011,Summer, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M

2011
The use of midazolam and haloperidol in cancer patients at the end of life.
    Singapore medical journal, 2012, Volume: 53, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Haloperidol; Humans; Hypnoti

2012
Inhibition of tumor cell growth by Sigma1 ligand mediated translational repression.
    Biochemical and biophysical research communications, 2012, Sep-21, Volume: 426, Issue:2

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Size; Haloperidol; Humans; Ligands; Morpholines; Neoplasm

2012
[Management of psychiatric symptoms in cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Antidepressive Agents; Delirium; Depression; Disease Management; Dopamine Antagonists; Haloperidol;

2002
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2003, Volume: 11, Issue:2

    Topics: Antiemetics; Butylscopolammonium Bromide; Drug Interactions; Drug Stability; Drug Storage; Haloperid

2003
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
    Pain, 2003, Volume: 103, Issue:1-2

    Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Di

2003
Use of sedation to relieve refractory symptoms in dying patients.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2004, Volume: 94, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Communication; Conscious Sedatio

2004
Stability of tramadol and haloperidol for continuous subcutaneous infusion at home.
    Journal of pain and symptom management, 2005, Volume: 30, Issue:2

    Topics: Analgesics, Opioid; Antipsychotic Agents; Chemical Phenomena; Chemistry, Physical; Drug Combinations

2005
Reversal of morphine with naloxone precipitates haloperidol-induced extrapyramidal side effects.
    Journal of pain and symptom management, 2006, Volume: 31, Issue:5

    Topics: Adolescent; Analgesics, Opioid; Antipsychotic Agents; Basal Ganglia Diseases; Drug Interactions; Fem

2006
[Psychiatry and sleep disorders--delirium].
    Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2006, Volume: 108, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I

2006
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
    The journal of supportive oncology, 2008, Volume: 6, Issue:1

    Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini

2008
Clinical evaluation of combined treatment with methadone and psychotropic drugs in cancer patients.
    Acta anaesthesiologica Scandinavica. Supplementum, 1982, Volume: 74

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Methadone; Middle Aged; M

1982
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:5

    Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperido

1996
The use of haloperidol to treat nausea.
    Oncology nursing forum, 1998, Volume: 25, Issue:8

    Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms

1998
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2002, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analgesics; Butylscopolammonium Bromide; Dexamethasone; Drug Evaluat

2002
[The treatment of chronic pain symptoms with psychotropic drugs (author's transl)].
    Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1976, Volume: 9, Issue:6

    Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bone Diseases; Clomipramine; Drug Therapy, C

1976
[Morphine-antiemetics mixtures for continuous subcutaneous infusion in terminal cancer].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1992, May-30, Volume: 112, Issue:14

    Topics: Antiemetics; Drug Combinations; Drug Stability; Haloperidol; Humans; Infusion Pumps, Implantable; Me

1992
Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients.
    Onkologie, 1991, Volume: 14, Issue:1

    Topics: Analgesics; Anticonvulsants; Antidepressive Agents; Clomipramine; Drug Therapy, Combination; Haloper

1991
Emergency intravenous sedation of the delirious, medically ill patient.
    The Journal of clinical psychiatry, 1988, Volume: 49 Suppl

    Topics: Critical Care; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Hydromorphone; Infusions, I

1988
Treatment of severe, refractory agitation with a haloperidol drip.
    The Journal of clinical psychiatry, 1988, Volume: 49, Issue:6

    Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M

1988
Emergency pharmacotherapy of delirium in the critically ill cancer patient.
    Psychosomatics, 1986, Volume: 27, Issue:1 Suppl

    Topics: Adult; Aged; Delirium; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Humans; Infusion

1986
Combined use of tricyclic antidepressants and neuroleptics in the management of terminally ill children: a report on three cases.
    Journal of the American Academy of Child Psychiatry, 1985, Volume: 24, Issue:4

    Topics: Adolescent; Amitriptyline; Anxiety Disorders; Child; Depressive Disorder; Drug Therapy, Combination;

1985
Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration.
    Current therapeutic research, clinical and experimental, 1973, Volume: 15, Issue:9

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Haloperidol; Humans; Male; Middle Aged; N

1973
[Collecting of the news].
    Minerva medica, 1974, Volume: 65, Issue:85 Suppl

    Topics: Aging; Air Pollution; Haloperidol; Health Education; Humans; Italy; Myocardial Infarction; Neoplasms

1974
A sensitive and selective approach for detection of IL 1α cancer biomarker using disposable ITO electrode modified with epoxy-substituted polythiophene polymer.
    Biosensors & bioelectronics, 2019, Nov-01, Volume: 144

    Topics: Antibodies, Immobilized; Biomarkers, Tumor; Biosensing Techniques; Dielectric Spectroscopy; Epoxy Re

2019
Immunohistochemistry on epoxy resin-embedded bone marrow biopsy experience with 936 cases.
    Applied immunohistochemistry & molecular morphology : AIMM, 2011, Volume: 19, Issue:1

    Topics: Biopsy; Bone Marrow; Case-Control Studies; Epoxy Resins; Female; Humans; Immunohistochemistry; Male;

2011
Cancer and coal tar epoxy resins.
    Journal of occupational medicine. : official publication of the Industrial Medical Association, 1989, Volume: 31, Issue:7

    Topics: Coal Tar; Epoxy Resins; Humans; Neoplasms; Occupational Diseases; Respiratory Tract Neoplasms; Risk

1989